Biogen Inc. is set to announce its fiscal Q4 earnings for 2025, with analysts predicting a profit of $1.72 per share, down 50% from the year-ago quarter. Despite this, the company has exceeded bottom-line estimates in three of the last four quarters, with a notable EPS of $4.81 in Q3.

For the current fiscal year, analysts expect Biogen to report a profit of $14.89 per share, down 9.6% from the previous year. However, the EPS is projected to rebound and grow marginally to $15.01 in fiscal 2026. The company has lagged behind the S&P 500 Index but outpaced XLV over the past 52 weeks.

Shares of Biogen rose 2.9% after RBC Capital reaffirmed its “Outperform” rating and maintained a $210 price target, naming the stock a top large-cap pick for 2026. Wall Street analysts are moderately optimistic about BIIB’s stock, with a mean price target of $187.11, indicating a 4.9% potential upside from current levels.

Read more at Yahoo Finance: What to Expect From Biogen’s Next Quarterly Earnings Report